Cencora, Inc. (LON:0HF3)
London · Delayed Price · Currency is GBP · Price in USD 369.23
-7.43 (-1.97%)
At close: Nov 26, 2025
Cencora Employees
Cencora had 51,000 employees as of September 30, 2025. The number of employees increased by 5,000 or 10.87% compared to the previous year.
Employees
51,000
Change (1Y)
5,000
Growth (1Y)
10.87%
Revenue / Employee
4.69M GBP
Profits / Employee
22.67K GBP
Market Cap
54.03B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 51,000 | 5,000 | 10.87% |
| Sep 30, 2024 | 46,000 | 0 | - |
| Sep 30, 2023 | 46,000 | 2,000 | 4.55% |
| Sep 30, 2022 | 44,000 | 2,000 | 4.76% |
| Sep 30, 2021 | 42,000 | 20,000 | 90.91% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| Spire Healthcare Group | 15,703 |
| ConvaTec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| Genus | 3,190 |
Cencora News
- 19 days ago - Cencora: Earnings Visibility Driving Re-Rating Potential - Seeking Alpha
- 21 days ago - Cencora, Inc. (COR) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Cencora to invest $1 billion on US drug distribution, posts upbeat 2026 forecast - Reuters
- 21 days ago - Drug Distributor Cencora to Invest $1 Billion in U.S. Supply Chain - WSJ
- 21 days ago - Cencora Announces $1 Billion Investment to Strengthen Its U.S. Distribution Network - Business Wire
- 21 days ago - Cencora Reports Fiscal 2025 Fourth Quarter and Fiscal Year End Results - Business Wire
- 25 days ago - ADP, Snap-on Lead 14 Companies To Announce Annual Increases In First Half Of November - Seeking Alpha
- 5 weeks ago - IntrinsiQ Specialty Solutions Expands Data Capabilities to Empower Biopharmaceutical Manufacturers and Physicians with Actionable Insights to Improve Patient Outcomes - Business Wire